NTLA
12.44 USD
+0.90%
Today
+4.38%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
4:30 PM ~ 10:59 PM
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
Intellia Therapeutics
Currency
USD
Market Cap
1.66B
Avg Daily Volume
4.39M
52 Week High
18.48 USD
52 Week Low
7.95 USD
Trading Hours
See hours
Business Summary
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Top News
Teradyne
-4.72%
AeroVironment
-4.34%
Joby.Aviation
+3.71%
Archer.Aviation
+2.91%
RobinHood
-0.67%
Illumina
+1.06%
Cerebras.Systems
-3.07%
Coinbase
+0.24%
Kratos
-5.76%
Tempus.AI
+1.75%
Beam_Therapeutics
+3.31%
PacificBio
+4.13%
Arcturus
+13.15%
Intellia
+3.88%
AMD.Inc
-8.18%
TwnSemiCon
-1.37%
EliLilly
+1.91%
ARKB
+1.94%
Twist_Bioscience
-1.66%
10X_Genomics
+5.54%
CareDx
+0.38%
CrowdStrike
+0.18%
CloudFlare
-4.38%
Rubrik
-2.23%
Cathie Wood's weekly recap: loads TER, AVAV after strong results; books gain in AMD, TSM, LLY
tradingview.com
2d ago
Intellia
+3.88%
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
tradingview.com
6d ago
Intellia
+3.88%
Intellia Therapeutics, Inc. (NTLA) Appoints Jing L. Marantz as CMO
tradingview.com
3w ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
